<p>Values for cytokine levels are mean (SD) pg/ml; n: all JDM = 54, controls = 54, JDM active = 28, JDM inactive = 26. p value when comparing cytokine levels in all JDM and controls; for the comparison active <i>vs</i> inactive JDM, no differences were detected. The cytokines shown were selected based on associations seen in the present and/or previous studies on dermatomyositis or other rheumatic diseases. JDM: juvenile dermatomyositis; MCP: monocyte chemoattractant protein; IP: interferon-inducible protein; IL: interleukine; TNF: tumor necrosis factor; Ra: receptor antagonist; TGF: transforming growth factor; Th1/Th2, IFN-γ/IL-4.</p
OBJECTIVE: Serum cytokines play an important role in the pathogenesis of myositis by initiating and ...
<p>MCP: monocyte chemoattractant protein; r: Spearman correlation coefficient; MDI: Myositis Damage ...
International audienceIntroduction: The aetiopathogenesis of juvenile dermatomyositis (JDM) remains ...
To compare cytokine profiles in patients with juvenile dermatomyositis (JDM) after medium to long-te...
<p>Values are number (%), median (range) or mean (SD). JDM: juvenile dermatomyositis; NA: not applic...
OBJECTIVE: Juvenile dermatomyositis (DM) is a systemic autoimmune disorder of unknown immunopathogen...
Easily accessible biomarkers are urgently needed to evaluate immune activation in Juvenile Dermatomy...
Juvenile Dermatomyositis (JDM) is a systemic immune-mediated disease of childhood, characterized by ...
Objective: Juvenile dermatomyositis (DM) is a heterogeneous systemic immune-mediated vasculopathy. T...
Anti-nuclear matrix protein 2 (NXP2) antibody-positive dermatomyositis (DM) is characterized by exte...
Objective To identify early factors associated with disease course in patients with juvenile idiopat...
Background: It is currently impossible to predict the prognosis of patients with juvenile dermatomyo...
Objective: This study determined if an accessible, serologic indicator of vascular disease activity,...
OBJECTIVE: Juvenile dermatomyositis (DM) is a heterogeneous systemic immune-mediated vasculopathy. T...
Objective Juvenile dermatomyositis (DM) is a heterogeneous systemic immune-mediated vasculopathy. Th...
OBJECTIVE: Serum cytokines play an important role in the pathogenesis of myositis by initiating and ...
<p>MCP: monocyte chemoattractant protein; r: Spearman correlation coefficient; MDI: Myositis Damage ...
International audienceIntroduction: The aetiopathogenesis of juvenile dermatomyositis (JDM) remains ...
To compare cytokine profiles in patients with juvenile dermatomyositis (JDM) after medium to long-te...
<p>Values are number (%), median (range) or mean (SD). JDM: juvenile dermatomyositis; NA: not applic...
OBJECTIVE: Juvenile dermatomyositis (DM) is a systemic autoimmune disorder of unknown immunopathogen...
Easily accessible biomarkers are urgently needed to evaluate immune activation in Juvenile Dermatomy...
Juvenile Dermatomyositis (JDM) is a systemic immune-mediated disease of childhood, characterized by ...
Objective: Juvenile dermatomyositis (DM) is a heterogeneous systemic immune-mediated vasculopathy. T...
Anti-nuclear matrix protein 2 (NXP2) antibody-positive dermatomyositis (DM) is characterized by exte...
Objective To identify early factors associated with disease course in patients with juvenile idiopat...
Background: It is currently impossible to predict the prognosis of patients with juvenile dermatomyo...
Objective: This study determined if an accessible, serologic indicator of vascular disease activity,...
OBJECTIVE: Juvenile dermatomyositis (DM) is a heterogeneous systemic immune-mediated vasculopathy. T...
Objective Juvenile dermatomyositis (DM) is a heterogeneous systemic immune-mediated vasculopathy. Th...
OBJECTIVE: Serum cytokines play an important role in the pathogenesis of myositis by initiating and ...
<p>MCP: monocyte chemoattractant protein; r: Spearman correlation coefficient; MDI: Myositis Damage ...
International audienceIntroduction: The aetiopathogenesis of juvenile dermatomyositis (JDM) remains ...